EXCLUSIVE-NETWORKS
3.3.2021 10:02:11 CET | Business Wire | Press release
Exclusive Networks, the global trusted digital infrastructure specialist, today announced its appointment of international channel veteran Denis Ferrand-Ajchenbaum to lead its global vendor strategy. A highly knowledgeable channel leader, Denis brings a proven scorecard of vendor success to his role where he will be responsible for maximising the value and global penetration of existing vendor relationships while scouting and acquiring the next generation of Exclusive Networks’ trust digital infrastructure portfolio. The ex-Arrow and IBM senior executive brings over 30 years’ leadership experience and extensive C-level connections gleaned from his Silicon Valley background and presence across technology forums.
“Our choice of vendors, and the relationships we have with them, is a keystone of the Exclusive Networks proposition and we believe there is significant additional value to come from implementing a strategy aligned to our trusted digital infrastructure mission,” said Jesper Trolle, CEO of Exclusive Networks. “Denis has exactly the right skills and experience to strengthen and harmonise our blend of vendor alliances, bringing huge growth opportunities to all our partners around the world. Having worked alongside him for many years, I am confident that Denis will hit the ground running and play a pivotal role in our future success.”
Denis Ferrand-Ajchenbaum has spent his entire career in enterprise IT, more than 20 years of which at value-added distributors on a national, regional and global scale. He joins Exclusive Networks from Arrow where his roles included leading global vendor management, developing EMEA product strategy, shaping its ‘advanced technology group’ vendor incubation business unit and, most recently, as VP Sales of its Arrowsphere cloud delivery platform. His other experience – in a variety of business development and sales positions – includes stints at IBM, Avnet and Clearpoint.
“I’m delighted to join Exclusive Networks as we embark on a new mission to enable a totally trusted world for people and organisations,” said Denis Ferrand-Ajchenbaum. “Our success to date has been a story of always being different in order to maintain momentum and keep our value model intact. We now need to consolidate and expand our global specialism in trusted digital infrastructure by filling out all market segments related to this, continuing to drive innovation and investing in our alliances with both existing and new vendor partners. The vendor landscape is multilayered and very fast moving, and I look forward to working closely with our vendor community and bringing them more closely together; enabling new opportunities through cross-selling and upselling, new consumption models, high-value services and greater global coordination.”
-ends-
About Exclusive Networks
Exclusive Networks Exclusive Networks is the global trusted digital infrastructure specialist driving the transition to a totally trusted digital future for all people and organisations. Our distinctive approach to distribution gives partners more opportunity and more customer relevance. Our specialism is their strength – equipping them to capitalise on rapidly evolving technologies and transformative business models.
The Exclusive Networks story is a global one with a services-first ideology at its core, harnessing innovation and disruption to outstrip market growth. With 50+ offices across five continents and presence in over 100 countries, Exclusive Networks has a unique ‘local sale, global scale’ model, combining the extreme focus and value of local independents with the scale and service delivery of a single worldwide distribution powerhouse. More at www.exclusive-networks.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210303005073/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
